DEVELOPMENT OF CHITOSAN/COLISTIN NANO ANTIBIOTICS AND THEIR IN VITRO ACTIVITY AGAINST MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII
Multidrug-resistant (MDR) Acinetobacter baumannii and Klebsiella pneumoniae cause serious hospital-acquired infections, for which colistin is often one of the final treatment options. However, its clinical utility is hindered by dose-related toxicity and resistance development. In this study, chitosan–colistin nanopart...